|
| TransTech Pharma and Boehringer Ingelheim Initiate $54 Million Drug Discovery Collaboration High Point, NC – December 21, 2005 TransTech Pharma, Inc. (TransTech) today announced a worldwide research and license collaboration with Boehringer Ingelheim GmbH using TransTech's proprietary TTP Translational Technology. The aim of the collaboration is to discover and develop novel small molecules as therapeutics against an undisclosed biological target of interest to both companies. Under the terms of the agreement, Boehringer Ingelheim has the exclusive right to develop and commercialize all compounds directed at the target covered by the collaboration. In a deal potentially valued at $54 million, TransTech would receive an upfront payment, research support and payments upon the achievement of specified research, clinical and commercialization milestones. In addition, TransTech would receive royalties on future product sales. Specific terms of the agreement were not disclosed. “Boehringer Ingelheim Research recognizes the importance of collaborating with specialized biotech companies to discover new lead chemical structures against challenging biological targets. The alliance with TransTech Pharma provides an innovative lead-finding technology to be combined with Boehringer Ingelheim's strength in drug discovery. We look forward to rapidly exploring this technology to identify drug candidates for a highly relevant biologic target“, said Prof. Mikael Dolsten, Head of Corporate Division Pharma Research, Boehringer Ingelheim. Adnan Mjalli, Ph.D., Founder, President and Chief Executive Officer of TransTech, said: “We are very excited to enter into this collaboration with Boehringer Ingelheim, a premier international pharmaceutical company, having special expertise and strength in the discovery and development of therapeutics to treat various human diseases. The coupling of Boehringer Ingelheim's development capabilities and our discovery engine, TTP Translational Technology®, is a powerful combination designed to result in the expedited discovery of novel, safe and effective clinical drug candidates.“ TransTech's TTP Translational Technology® is a highly automated and fully integrated drug discovery process including proprietary software modules. The technology already has shown to work effectively against a wide range of biological targets including protein-protein interactions, receptor modulators and enzyme inhibitors, and delivered small-molecule-based pre-clinical and clinical drug candidates for the treatment of diabetes, cancer, inflammation, Alzheimer's disease and thrombosis. TransTech Pharma is a privately held clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of human therapeutics to fill unmet medical needs. The Company’s high-throughput drug discovery platform, Translational Technology®, translates the functional modulation of human proteins into safe and effective medicines. TransTech has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including cardiovascular disorders, central nervous system disorders, type I/II diabetes, obesity, and oncology. For further company information, visit http://www.ttpharma.com The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2004, Boehringer Ingelheim posted net sales of 8.2 billion euro while spending nearly one fifth of net sales in its largest business segment Prescription Medicines on research and development. For further company information visit www.boehringer-ingelheim.com. For further information contact: Adnan Mjalli, PhD
|
|||||
|
|